Lv7
4040 积分 2025-03-05 加入
Management of Central Nervous System Progression with Dose-Escalated Lorlatinib in ALK-Positive NSCLC: A Report of Two Cases and Literature Review
6个月前
已完结
A matching-adjusted indirect comparison of first-line lorlatinib and alectinib for the treatment of ALK-rearranged advanced non-small cell lung cancer
6个月前
已完结
High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs
6个月前
已完结
Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors
6个月前
已完结
EGFR T790M mutation testing within the osimertinib AURA Phase I study
6个月前
已完结
Radiopharmaceuticals in the Management of Leptomeningeal Metastasis
6个月前
已完结
Radiopharmaceuticals in the Management of Leptomeningeal Metastasis
6个月前
已关闭
Radiopharmaceuticals in the Management of Leptomeningeal Metastasis
6个月前
已关闭
Proton Craniospinal Irradiation for Patients With Leptomeningeal Metastasis: A Randomized Clinical Trial
6个月前
已完结
Physicochemical and biological characterization of a bispecific antibody in a CrossMab/KIH format that targets EGFR and VEGF-A
8个月前
已完结
皖公网安备34019202002308
